Modulation of Enhancer Looping and Differential Gene Targeting by Epstein-Barr Virus Transcription Factors Directs Cellular Reprogramming

PLoS Pathogens

Volumn 9, Issue 9, 2013, Pages

  McClellan, Michael J ^a   Wood, C David ^a   Ojeniyi, Opeoluwa ^a   Cooper, Tim J ^a   Kanhere, Aditi ^b,e   Arvey, Aaron ^c   Webb, Helen M ^a   Palermo, Richard D ^a,f   Harth Hertle, Marie L ^d   Kempkes, Bettina ^d   Jenner, Richard G ^b   West, Michelle J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; C TERMINAL BINDING PROTEIN 2; E1A ASSOCIATED P300 PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3; HISTONE H3; INTERFERON REGULATORY FACTOR 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IIB; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR WEE1; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; ALCOHOL DEHYDROGENASE; CELL CYCLE PROTEIN; CTBP2 PROTEIN, HUMAN; EBNA-2 PROTEIN, HUMAN HERPESVIRUS 4; EBNA-3A ANTIGEN; EBNA-3B ANTIGEN; EBNA-3C, EPSTEIN-BARR VIRUS; EPSTEIN BARR VIRUS ANTIGEN; NERVE PROTEIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; REPRESSOR PROTEIN; WEE1 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; BINDING SITE; CELLULAR REPROGRAMMING; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENHANCER REGION; EPSTEIN BARR VIRUS; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; PROCEDURES CONCERNING CELLS; PROMOTER REGION; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; BINDING COMPETITION; BIOLOGICAL MODEL; CELL LINE; CHEMISTRY; EPSTEIN BARR VIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; NUCLEAR REPROGRAMMING; PATHOLOGY;

ALCOHOL OXIDOREDUCTASES; BINDING SITES; BINDING, COMPETITIVE; CELL CYCLE PROTEINS; CELL LINE; CELLULAR REPROGRAMMING; ENHANCER ELEMENTS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE TARGETING; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; VIRAL PROTEINS;

EID: 84884685804     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003636     Document Type: Article

References (105)

1. Epstein MA, Achong BG, Barr YM, (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 15: 702-703.
2. Cohen JI, Wang F, Mannick J, Kieff E, (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 86: 9558-9562.
3. Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, et al. (1995) B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. Embo J 14: 88-96.
4. Laux G, Dugrillon F, Eckert C, Adam B, Zimber-Strobl U, et al. (1994) Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol 68: 6947-6958.
5. Woisetschlaeger M, Jin XW, Yandava CN, Furmanski LA, Strominger JL, et al. (1991) Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A 88: 3942-3946.
6. Zimber-Strobl U, Kremmer E, Grasser F, Marschall G, Laux G, et al. (1993) The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. Embo J 12: 167-175.
7. Wang F, Tsang SF, Kurilla MG, Cohen JI, Kieff E, (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64: 3407-3416.
8. Cordier M, Calender A, Billaud M, Zimber U, Rousselet G, et al. (1990) Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol 64: 1002-1013.
9. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, et al. (1999) The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 73: 4481-4484.
10. Knutson JC, (1990) The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol 64: 2530-2536.
11. Spender LC, Cornish GH, Sullivan A, Farrell PJ, (2002) Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol 76: 4919-4927.
12. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E, (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A 91: 7568-7572.
13. Henkel T, Ling PD, Hayward SD, Peterson MG, (1994) Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265: 92-95.
14. Waltzer L, Logeat F, Brou C, Israel A, Sergeant A, et al. (1994) The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. Embo J 13: 5633-5638.
15. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, et al. (1995) Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 69: 253-262.
16. Sjoblom A, Yang W, Palmqvist L, Jansson A, Rymo L, (1998) An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol 72: 1365-1376.
17. Zhao B, Zou J, Wang H, Johannsen E, Peng CW, et al. (2011) Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A 108: 14902-14907.
18. Fuentes-Panana EM, Peng R, Brewer G, Tan J, Ling PD, (2000) Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway. J Virol 74: 8166-8175.
19. Cohen JI, Kieff E, (1991) An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol 65: 5880-5885.
20. Cohen JI, (1992) A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A 89: 8030-8034.
21. Tong X, Drapkin R, Reinberg D, Kieff E, (1995) The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A 92: 3259-3263.
22. Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E, (1995) The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol 15: 4735-4744.
23. Tong X, Wang F, Thut CJ, Kieff E, (1995) The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol 69: 585-588.
24. Wang L, Grossman SR, Kieff E, (2000) Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci U S A 97: 430-435.
25. Wu DY, Krumm A, Schubach WH, (2000) Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol 74: 8893-8903.
26. Wu DY, Kalpana GV, Goff SP, Schubach WH, (1996) Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol 70: 6020-6028.
27. Harada S, Kieff E, (1997) Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 71: 6611-6618.
28. Nitsche F, Bell A, Rickinson A, (1997) Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol 71: 6619-6628.
29. Sinclair AJ, Palmero I, Peters G, Farrell PJ, (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13: 3321-3328.
30. Portal D, Rosendorff A, Kieff E, (2006) Epstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci U S A 103: 19278-19283.
31. Tomkinson B, Robertson E, Kieff E, (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67: 2014-2025.
32. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, et al. (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5: e1000506.
33. Maruo S, Johannsen E, Illanes D, Cooper A, Kieff E, (2003) Epstein-Barr Virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 77: 10437-10447.
34. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, et al. (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A 103: 19500-19505.
35. Tomkinson B, Kieff E, (1992) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66: 2893-2903.
36. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, et al. (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122: 1487-1502.
37. McClellan MJ, Khasnis S, Wood CD, Palermo RD, Schlick SN, et al. (2012) Downregulation of Integrin Receptor-Signaling Genes by Epstein-Barr Virus EBNA 3C via Promoter-Proximal and-Distal Binding Elements. J Virol 86: 5165-5178.
38. White RE, Groves IJ, Turro E, Yee J, Kremmer E, et al. (2010) Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5: e13979.
39. Zhao B, Mar JC, Maruo S, Lee S, Gewurz BE, et al. (2011) Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 108: 337-342.
40. Bain M, Watson RJ, Farrell PJ, Allday MJ, (1996) Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol 70: 2481-2489.
41. Marshall D, Sample C, (1995) Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol 69: 3624-3630.
42. Waltzer L, Perricaudet M, Sergeant A, Manet E, (1996) Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 70: 5909-5915.
43. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, et al. (1995) Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 69: 3108-3116.
44. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M, (1994) The Epstein-Barr virus determined nuclear antigens EBNA-3A,-3B, and-3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205: 596-602.
45. Zhao B, Sample CE, (2000) Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 74: 5151-5160.
46. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ, (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 277: 47197-47204.
47. Knight JS, Lan K, Subramanian C, Robertson ES, (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77: 4261-4272.
48. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ, (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40: 7233-7246.
49. Radkov SA, Touitou R, Brehm A, Rowe M, West M, et al. (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73: 5688-5697.
50. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ, (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75: 7749-7755.
51. Subramanian C, Hasan S, Rowe M, Hottiger M, Orre R, et al. (2002) Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. J Virol 76: 4699-4708.
52. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, et al. (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919-1924.
53. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ, (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
54. Anderton E, Yee J, Smith P, Crook T, White RE, et al. (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421-433.
55. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, et al. (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
56. Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, et al. (2008) Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol 82: 7456-7466.
57. Maier S, Staffler G, Hartmann A, Hock J, Henning K, et al. (2006) Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 80: 9761-9771.
58. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, et al. (2006) Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol 87: 2859-2867.
59. Zhao B, Maruo S, Cooper A, M RC, Johannsen E, et al. (2006) RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 103: 1900-1905.
60. Gregory CD, Rowe M, Rickinson AB, (1990) Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71 (Pt 7):: 1481-1495.
61. Chen A, Zhao B, Kieff E, Aster JC, Wang F, (2006) EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 80: 10139-10150.
62. Skalska L, White RE, Parker GA, Sinclair AJ, Paschos K, et al. (2013) Induction of p16(INK4a) Is the Major Barrier to Proliferation when Epstein-Barr Virus (EBV) Transforms Primary B Cells into Lymphoblastoid Cell Lines. PLoS Pathog 9: e1003187.
63. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, et al. (2009) Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459: 108-112.
64. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, et al. (2010) Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 107: 21931-21936.
65. Rada-Iglesias A, Bajpai R, Swigut T, Brugmann SA, Flynn RA, et al. (2011) A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470: 279-283.
66. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, et al. (2012) Architecture of the human regulatory network derived from ENCODE data. Nature 489: 91-100.
67. Chinnadurai G, (2009) The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. Cancer Res 69: 731-734.
68. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, et al. (2004) The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23: 1342-1353.
69. Schlick SN, Wood CD, Gunnell A, Webb HM, Khasnis S, et al. (2011) Upregulation of the Cell-Cycle Regulator RGC-32 in Epstein-Barr Virus-Immortalized Cells. PLoS One 6: e28638.
70. Wade M, Allday MJ, (2000) Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 20: 1344-1360.
71. Calender A, Cordier M, Billaud M, Lenoir GM, (1990) Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int J Cancer 46: 658-663.
72. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, et al. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64: 2309-2318.
73. Naumova N, Smith EM, Zhan Y, Dekker J, (2012) Analysis of long-range chromatin interactions using Chromosome Conformation Capture. Methods 58: 192-203.
74. Bulger M, Groudine M, (2011) Functional and mechanistic diversity of distal transcription enhancers. Cell 144: 327-339.
75. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, et al. (2010) 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 107: 9742-9746.
76. Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, et al. (2012) Epigenomic enhancer profiling defines a signature of colon cancer. Science 336: 736-739.
77. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, et al. (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41: 882-884.
78. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, et al. (2009) The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41: 885-890.
79. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, et al. (1993) A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. Embo J 12: 469-478.
80. Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, et al. (1995) Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A 92: 10467-10471.
81. Paliwal S, Ho N, Parker D, Grossman SR, (2012) CtBP2 Promotes Human Cancer Cell Migration by Transcriptional Activation of Tiam1. Genes Cancer 3: 481-490.
82. Nurse P, (1975) Genetic control of cell size at cell division in yeast. Nature 256: 547-551.
83. O'Nions J, Allday MJ, (2004) Deregulation of the cell cycle by the Epstein-Barr virus. Adv Cancer Res 92: 119-186.
84. Saha A, Robertson ES, (2013) Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis. Future Microbiol 8: 323-352.
85. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES, (2007) The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol 81: 6718-6730.
86. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, et al. (2010) An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8: 510-522.
87. Long EO, (2011) ICAM-1: getting a grip on leukocyte adhesion. J Immunol 186: 5021-5023.
88. Mor A, Dustin ML, Philips MR, (2007) Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunol Rev 218: 114-125.
89. Smith A, Stanley P, Jones K, Svensson L, McDowall A, et al. (2007) The role of the integrin LFA-1 in T-lymphocyte migration. Immunol Rev 218: 135-146.
90. Kintner C, Sugden B, (1981) Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus. Nature 294: 458-460.
91. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, et al. (1988) Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62: 4173-4184.
92. Wang F, Gregory CD, Rowe M, Rickinson AB, Wang D, et al. (1987) Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A 84: 3452-3456.
93. Chopra VS, Kong N, Levine M, (2012) Transcriptional repression via antilooping in the Drosophila embryo. Proc Natl Acad Sci U S A 109: 9460-9464.
94. Banerjee S, Lu J, Cai Q, Saha A, Jha HC, et al. (2013) The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog 9: e1003314.
95. Eisenbeis CF, Singh H, Storb U, (1995) Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 9: 1377-1387.
96. Lu F, Wikramasinghe P, Norseen J, Tsai K, Wang P, et al. (2010) Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). Virol J 7: 262.
97. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM, et al. (1977) Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer 19: 27-33.
98. Kelly GL, Milner AE, Tierney RJ, Croom-Carter DS, Altmann M, et al. (2005) Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A,-3B, and-3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 79: 10709-10717.
99. Chen A, Divisconte M, Jiang X, Quink C, Wang F, (2005) Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79: 4506-4509.
100. Bark-Jones SJ, Webb HM, West MJ, (2006) EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5. Oncogene 25: 1775-1785.
101. Palermo RD, Webb HM, West MJ, (2011) RNA Polymerase II Stalling Promotes Nucleosome Occlusion and pTEFb Recruitment to Drive Immortalization by Epstein-Barr Virus. PLoS Pathog 7: e1002334.
102. Maunders MJ, Petti L, Rowe M, (1994) Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. J Gen Virol 75 (Pt 4):: 769-778.
103. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137.
104. Tempera I, Klichinsky M, Lieberman PM, (2011) EBV latency types adopt alternative chromatin conformations. PLoS Pathog 7: e1002180.
105. West MJ, Webb HM, Sinclair AJ, Woolfson DN, (2004) Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J Virol 78: 9431-9445.